Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) will present a poster at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The poster will examine the effects of TONMYA (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function. According to the announcement, the presentation underscores Tonix's commitment to advancing research in pain management and supporting its flagship medicine.
TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025. It is the first new treatment for fibromyalgia in more than 15 years, addressing a significant unmet need for patients with this chronic condition. The upcoming data presentation at a major international pain congress may help raise awareness among clinicians and researchers about TONMYA's potential benefits beyond its approved indication, reinforcing its clinical profile.
Tonix is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments. Its CNS commercial infrastructure supports marketed products including acute migraine therapies Zembrace SymTouch and Tosymra. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, which could expand the drug's label into additional indications and drive long-term growth.
The IASP World Congress on Pain is a global forum that attracts pain specialists, researchers, and healthcare professionals. Presenting TONMYA data there may enhance Tonix's visibility and credibility in the pain field, potentially accelerating adoption and fostering collaborations. For investors, the presentation could serve as a catalyst by demonstrating the company's ongoing research efforts and the broader potential of its lead asset.
Tonix's pipeline also includes TNX-2900 for Prader-Willi syndrome, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for the prevention of kidney transplant rejection. These candidates are investigational, and their efficacy and safety have not been established. The company's diversified approach may provide multiple shots on goal, but the near-term focus remains on TONMYA's commercial execution and clinical expansion.
For ongoing updates, the company's newsroom is available at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/jFHh3. This news is distributed through TinyGems, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For important disclosures, see the https://www.TinyGems.com/Disclaimer.
